Wells Fargo & Company Issues Pessimistic Forecast for Cellectis (NASDAQ:CLLS) Stock Price

Cellectis (NASDAQ:CLLS) had its price target decreased by analysts at Wells Fargo & Company from $4.00 to $3.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 63.93% from the stock’s previous close.

Other analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays started coverage on Cellectis in a research note on Thursday, May 28th. They set an “overweight” rating and a $9.00 price target for the company. Finally, Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Cellectis Stock Down 41.0%

Cellectis stock opened at $1.83 on Tuesday. Cellectis has a twelve month low of $1.75 and a twelve month high of $5.48. The firm has a 50 day moving average price of $3.00 and a 200-day moving average price of $3.34. The company has a market capitalization of $183.62 million, a P/E ratio of -2.82 and a beta of 2.92. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The company had revenue of $6.90 million for the quarter, compared to analysts’ expectations of $11.05 million.

Institutional Trading of Cellectis

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC purchased a new stake in Cellectis S.A. (NASDAQ:CLLS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis News Roundup

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to focus on in vivo gene-editing treatments for chronic diseases, a strategy that could create a more scalable platform and support longer-lasting therapies. Cellectis Announces Strategic Transformation to In Vivo Gene-Editing Company
• Neutral Sentiment: Citizens JMP reaffirmed its “market perform” rating, indicating limited near-term conviction while the company undergoes the transformation. CLLS Stock Heads for 14-Month Low After 40% Rout
• Negative Sentiment: Cellectis is exiting development of its lasme-cel and eti-cel programs as part of the pivot. Abandoning these cancer programs removes existing pipeline catalysts and contributed to the selloff. Cellectis Announces In Vivo Gene-Editing Transformation
• Negative Sentiment: Citizens JMP flagged delayed catalysts following the cancer-pipeline pivot, suggesting investors may face a longer wait for meaningful clinical or commercial progress. Delayed Cellectis Catalysts After Cancer Pipeline Pivot
• Negative Sentiment: The stock fell below its 50-day moving average and approached a 14-month low, signaling deteriorating momentum and potentially encouraging additional technical selling. Cellectis Share Price Crosses Below Fifty-Day Moving Average

Cellectis Company Profile

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.